Format

Send to

Choose Destination
J Dermatolog Treat. 2015;26(4):373-5. doi: 10.3109/09546634.2014.952608. Epub 2014 Aug 26.

Open-label exploratory study of acitretin for the treatment of severe chronic hand dermatitis.

Author information

1
Windsor Clinical Research Inc ., Windsor , Canada and.

Abstract

INTRODUCTION:

Acitretin is a retinoid approved for the treatment of psoriasis that has good efficacy for palmoplantar psoriasis. The safety and efficacy of acitretin in severe chronic hand dermatitis (CHD) is unknown.

METHODS:

A total of nine patients with severe CHD were enrolled and treated with acitretin 10 mg once daily which could be increased to 30 mg daily if well-tolerated. Patients were treated for up to 24 or 12 weeks if the physician global assessment (PGA) was clear or almost clear at that time. CHD severity was evaluated using a 5-grade PGA scale and the modified total lesion symptom score (mTLSS).

RESULTS:

The proportion of patients achieving PGA of clear or almost clear was 33.3% (95% CI: 9-69%) and the proportion achieving PGA of clear, almost clear or mild was 44% (95% CI: 15-77%). The mTLSS decreased by 45% (-6.3 ± 4.7; p = 0.02). Three patients did not complete the study: one due to an increase in facial dermatitis, one due to lack of efficacy and one who withdrew consent.

CONCLUSIONS:

This pilot study suggests that acitretin could improve severe CHD. Further studies are needed to better assess the efficacy and safety of acitretin in patients with severe CHD.

KEYWORDS:

Alitretinoin and hand eczema; palmoplantar; retinoid

PMID:
25102893
DOI:
10.3109/09546634.2014.952608
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center